Show simple item record

dc.contributor.authorWeir, Matthew R
dc.contributor.authorChen, Yen-Wen
dc.contributor.authorHe, Jinghua
dc.contributor.authorBookhart, Brahim
dc.contributor.authorCampbell, Alicia
dc.contributor.authorAshton, Veronica
dc.date.accessioned2021-11-18T19:01:06Z
dc.date.available2021-11-18T19:01:06Z
dc.date.issued2021-10-26
dc.identifier.urihttp://hdl.handle.net/10713/17160
dc.description.abstractIntroduction: Nonvalvular atrial fibrillation (NVAF) is associated with a substantial economic burden, particularly in patients with comorbid conditions. This study compared healthcare resource utilization (HRU) and costs of rivaroxaban and warfarin in patients with NVAF, obesity, and diabetes. Methods: A de-identified healthcare claims database was used to identify adult patients newly initiating rivaroxaban or warfarin and having at least one medical claim with a diagnosis of AF, obesity determined by validated algorithm, and at least one claim with a diagnosis of diabetes or for antidiabetic medication from December 2011 to March 2020. Propensity score matching was used to balance the treatment cohorts on the basis of demographics and baseline characteristics. All-cause and NVAF-related HRU rates and costs were compared between treatments using rate ratios, and mean cost differences were calculated on a per patient per year (PPPY) basis. Results: A total of 9999 matched pairs of patients with NVAF, obesity, and diabetes were identified in the rivaroxaban and warfarin cohorts. Rate ratios of all-cause HRU were significantly reduced with rivaroxaban versus warfarin in all healthcare settings evaluated, except emergency room visits. The greatest impact was on physician office visits followed by hospital outpatient and inpatient visits. NVAF-related HRU was significantly lower for rivaroxaban versus warfarin in all care settings. Consistent with these findings, the length of hospital stay was significantly reduced by approximately 4 days among all patients for both all-cause and NVAF-related hospitalizations in the rivaroxaban cohort compared with the warfarin cohort. Rivaroxaban was associated with reductions in all-cause total healthcare costs by more than $5000 PPPY and NVAF-related medical costs by approximately $1100 PPPY. Conclusion: In comparison with warfarin, rivaroxaban reduced HRU and costs, particularly hospital inpatient and outpatient visits and physician office visits, in patients with NVAF and comorbidities of obesity and diabetes.en_US
dc.description.urihttps://doi.org/10.1007/s13300-021-01161-4en_US
dc.description.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/pmc8586051/en_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofDiabetes Therapy : Research, Treatment and Education of Diabetes and Related Disordersen_US
dc.rights© 2021. The Author(s).en_US
dc.subjectAnticoagulationen_US
dc.subjectCostsen_US
dc.subjectDiabetes mellitusen_US
dc.subjectHealthcare resource utilizationen_US
dc.subjectNonvalvular atrial fibrillationen_US
dc.subjectObesityen_US
dc.subjectReal-world evidenceen_US
dc.subjectRivaroxabanen_US
dc.subjectWarfarinen_US
dc.titleHealthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetesen_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s13300-021-01161-4
dc.identifier.pmid34699020
dc.source.volume12
dc.source.issue12
dc.source.beginpage3167
dc.source.endpage3186
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record